Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. (2008)

Peer-Reviewed Study · Patel H, Mick R, Finlay J, Zhu TC, Rickter E, Cengel KA, Malkowicz SB, Hahn SM, Busch TM · August 1, 2008

Patel H et al., 2008-08-01: In 17 patients in a phase I motexafin lutetium PDT trial, serum PSA rose 98% at 24 hours after illumination, and higher PDT dose produced a longer biochemical delay. The clearest published prostate-PDT/PSA interaction, but the sensitiser is motexafin lutetium, not methylene blue.

At 24 hours after PDT, serum PSA increased by 98% +/- 36% (mean +/- SE) relative to baseline levels (P = 0.007).

Patel H et al., 2008-08-01: In 17 patients in a phase I motexafin lutetium PDT trial, serum PSA rose 98% at 24 hours after illumination, and higher PDT dose produced a longer biochemical delay. The clearest published prostate-PDT/PSA interaction, but the sensitiser is motexafin lutetium, not methylene blue. C3 (also C8). Study type: phase I trial, secondary PSA analysis. N: 17 patients. Country: USA (University of Pennsylvania). Drug: motexafin lutetium; PDT dose = measured photosensitiser level x in situ light dose. Funder: NCI R01 CA109456, R01 CA085831, P01 CA087971 per GrantList. Conflicts: not captured. Comparator: high vs low PDT dose by median split. No methylene blue arm. Study type: uncontrolled series.